Single-use Bioprocessing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Single-use Bioprocessing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Single-use Bioprocessing market is projected to register a CAGR of 11.5% during the forecast period (2022 – 2027).

The initial phase of the pandemic has had a substantial impact on the growth of the single-use bioprocessing market owing to the significant decline in manufacturing processes and restricted demand and supply of the drugs. However, single-use technology (SUT) has become a leading technology in pre-commercial manufacturing, including preclinical and clinical scales. With the increasing number of COVID-19 cases, the demand for effective drugs and a large number of vaccines were increased which has increased the adoption of single-use bioprocessing systems and technology by the biopharmaceutical companies due to fewer chances of contamination and reduced sterilization tests between the batches. Also, drug discovery using single-use technologies has become a major focus for the management of the pandemic. For instance, most of the COVID-19 vaccine research is based on single-use technologies. These efforts involve the use of novel approaches, such as mRNA and DNA technologies. hence, the studied market is significantly impacted by the COVID-19 pandemic.

Certain factors that are propelling the market growth are faster implementation and lower risk of product cross-contamination, increasing demand for biopharmaceuticals, lower costs, and lesser environmental impact of single-use bioprocessing technologies.

With the increasing demand for biopharmaceuticals due to the increasing number of chronic diseases among the population, the need for effective drugs and products is increasing which is likely to increase the demand for single-use technologies, thereby propelling the market growth. For instance, according to the Food Drug Administration, in 2021, 14 biologics were approved for the treatment of various chronic diseases. Therefore, the growing number of biological approvals is expected to increase the biopharmaceutical manufacturing process, which is expected to increase the utilization and adoption of single-use bioprocessing technologies and systems over the forecast period.

In addition, the single-use technologies and systems aid biopharmaceutical manufacturers in overcoming the manufacturers eliminating the risks of contamination, and reducing the need for sterilization between batches, hence improving efficiency. In addition, companies are focusing on developing a new single-use system which are utilized in both upstream and downstream processing of the production of biopharmaceuticals.

Also, the product's low water use, excellent energy efficiency, small footprint, and low risk of contamination are all factors that are fostering market expansion. The adoption of big data-based machine learning in the single-use system, which helps to increase product or drug yield and achieve maximum productivity and efficiency in terms of process, as well as a mainstream strategy by many biopharmaceutical manufacturers, are all contributing to the growth of the single-use bioprocessing market.

Moreover, the increasing company activities and rising adoption of various business strategies such as collaborations, partnerships, and product launches are also contributing to the growth of the market. For instance, in May 2021, Qosina entered into a distribution agreement with Nordson MEDICAL, to support Single-Use Bioprocess Integrators and Medical Device Manufacturers.

However, the issues related to leachable and extractable are likely to restrain the market growth over the forecast period.

Key Market TrendsBiopharmaceutical Manufacturer End User Segment Expects to Register a High CAGR in the Forecast Period

The Biopharmaceutical Manufacturer End User Segment is expected to witness significant growth in the Single-use bioprocessing market over the forecast period owing to the factors such as rising adoption of single-use technologies and systems due to the advantages, reduced initial investment and research and development cost, low cost of labor and material, and is easily disposed of, offered over conventional bioprocessing methods, increasing demand for biologics, and rising company activities.

The COVID-19 pandemic has affected the supply chain of pharmaceutical products. The restrictions on pharmaceutical manufacturing and export had affected many products sold in countries, such as the United States, Europe, and other countries. Amid the COVID-19 pandemic, the health systems of countries are rapidly investing in research and development to combat the virus. To screen SARS-CoV-2 against a library of 50,000 compounds, it is necessary to use a single-use bioreactor for flexibility and speed, while keeping the total operating expenditure to a minimum. For instance, in India, the Vaccine Task Force (VTF) set up by Prime Minister’s Office (PMO) for focused research on coronavirus vaccines has allowed research institutions and laboratories to use patient samples for research and development (R&D) purposes. The government has framed detailed guidelines for sharing bio-specimen and data for such research among institutions.

Furthermore, the rising company activities in developing single-use systems and consumables and adopting various business strategies are also contributing to the growth of the segment. for instance, in March 2021, Thermo Fischer Scientific launched 3,000 L and 5,000 L HyPerforma DynaDrive Single-use Bioreactors. These bioreactors offer features that support cell culture performance across scales and accommodate high-density and next-generation cell culture processes. DynaDrive S.U.B.s also provide superior turn-down in stirred tank reactors, which lowers the number of vessels needed for seed-train scale-up. By minimizing seed-train and enabling large-scale, high-intensity processes, the DynaDrive S.U.B.s reduce overall costs through reduced capital investment, reduced operational expenses, and higher-output processes. Also, in December 2020, Thermo Fisher Scientific launched a single-use bioreactor (SUB) for cell culture production.

Moreover, these single-use bioprocessing plants have a 35% more favorable carbon dioxide (CO2) balance than stainless steel reactors, which are used in conventional bioprocessing, and are highly adopted by the manufacturer. Also, the companies are opening up single-use bioprocessing plants to expand their protein, cell line, and process development services. For instance, in April 2022, Thermo Fisher Scientific opened a 55,000 square-foot single-use technology (SUT) facility in Ogden, to increase the production of single-use bioprocess containers for developing vaccines and therapies. The plant provides additional capacity to produce various techniques and materials needed for the development of emerging vaccines and breakthrough therapies. The facility will manufacture customizable bioprocess container (BPC) systems, which are used for the delivery, processing, separation, storage, and transportation of liquids.

Therefore, owing to the aforementioned factors, the studied market is expected to have significant growth in the region over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the Single-use Bioprocessing market, throughout the forecast period owing to the factors such as increasing research and development spending, the presence of largescale manufacturing units, the growing popularity of disposables, and increasing healthcare expenditure, and the presence of well-established healthcare infrastructure.

The United States is the most COVID-affected country in the world. The supply chain of products was highly impacted in this country. Initially, there is a decline in demand for single-use bioprocessing products, which has negatively impacted the overall market growth. However, with the growing awareness regarding the importance and benefits of single-use bioprocessing technologies, the demand for the same may gradually increase.

Additionally, the government is investing enormously in the development of vaccines, drugs, and diagnostic tests for the treatment of COVID-19, which is likely to drive the market for single-use bioreactors, thus, ultimately driving the overall market growth. For instance, in March 2020, the government of Canada announced CAD 275 million (EUR 179 million) for the research and development activities related to antivirals, diagnostics, vaccines, and clinical trials for COVID-19. Also, in April 2020, Moderna Inc. received USD 483 million from the government of the United States for the development of the vaccine against COVID-19.

The adoption of disposables has become a trend among contract manufacturing organizations (CMO), and this region is recognized as a significant market for contract service providers. This factor catalyzes continued investments by local and global companies for the implementation of disposables in the contract development and manufacturing organizations and biomanufacturing plants in the region.

Furthermore, the rising company activities in establishing sing-use bioprocessing plants and launching bioreactors and consumables are also contributing to the growth of the market over the forecast period. For instance, in May 2022, ILC Dover Lp launched liquid single-use bioprocessing bags for handling and supplying sterile liquids for the biotherapeutics market. This launch helps the company in expanding its product offerings in the single-use bioprocessing market. Also, in November 2021, Bionova opened a USD 25 million single-use plants in Fremont, California. The plant is equipped with a 1,000 L Cytiva XDR upstream train. In addition, the company will add a 2,000 L Cytiva system by Q3'2022.

Therefore, owing to the aforementioned factors, the studied market is expected to have significant growth in the region over the forecast period.

Competitive Landscape

The single-use bioprocessing market is moderately competitive and consists of several major players. Some of the companies, which are currently dominating the market are Sartorius AG, Thermo Fisher Scientific, Cytiva, Eppendorf AG, Merck KGaA, 3M, Infors AG, Boehringer Ingelheim International GmbH, and PBS Biotech.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.